Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Comparison of current western interventions, traditional Chinese formulations and proprietary ES17 on the treatment of osteoporosis

EF 2018-19

Résumé
Osteoporosis is a chronic skeletal disease primarily affecting post-menopausal women and men over the age of 50. Current pharmacological interventions, such as bisphosphonates and denosumab, target the bone resorption process and have limitations in efficacy due to the disruption of important bone remodeling mechanisms and thus also reducing bone formation. Cathepsin K (CatK) is an enzyme that is capable of breaking down collagen in the bone matrix, therefore inhibitors of CatK have been a new approach to the treatment of osteoporosis without affecting bone formation. Several CatK inhibitors such as odanacatib (ODN) have shown high efficacy in clinical trials, but were not approved due to adverse effects. Previously, a compound known as tashinone IIA sulfonic sodium (T06), was derived from Salvia miltiorrhiza (SM), a herb used in traditional Chinese medicine (TCM) for the treatment of cardiovascular and bone related disease. We have found that T06 specifically inhibits the bone-degrading activity of CatK with no significant side effects. Our laboratory has developed a proprietary tashinone-derivative compound, ESI7, with improved potency and pharmacokinetic measures. The major aim of this project will be to compare the efficacy of this compound to other tanshinone-containing herbal formulations and current Western interventions through in vitro and in vivo experiments. In vitro experiments will be conducted to determine the comparative inhibition of collagen degradation. In vivo mice experiments will be conducted to assess for bone-preserving efficacy and potential side effects after a four months period of treatment. We hope to introduce a new therapeutic treatment option for osteoporotic patients with increased efficacy in the absence of significant adverse events.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
418709
Name
Zhou Rujing
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Comparison of current western interventions, traditional Chinese formulations and proprietary ES17 on the treatment of osteoporosis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adverse Effects; Bone; Drug Interventions; Osteoporosis, Cathepsin K Inhibitors; Traditional Chinese Medicine
Abstract
Osteoporosis is a chronic skeletal disease primarily affecting post-menopausal women and men over the age of 50. Current pharmacological interventions, such as bisphosphonates and denosumab, target the bone resorption process and have limitations in efficacy due to the disruption of important bone remodeling mechanisms and thus also reducing bone formation. Cathepsin K (CatK) is an enzyme that is capable of breaking down collagen in the bone matrix, therefore inhibitors of CatK have been a new approach to the treatment of osteoporosis without affecting bone formation. Several CatK inhibitors such as odanacatib (ODN) have shown high efficacy in clinical trials, but were not approved due to adverse effects. Previously, a compound known as tashinone IIA sulfonic sodium (T06), was derived from Salvia miltiorrhiza (SM), a herb used in traditional Chinese medicine (TCM) for the treatment of cardiovascular and bone related disease. We have found that T06 specifically inhibits the bone-degrading activity of CatK with no significant side effects. Our laboratory has developed a proprietary tashinone-derivative compound, ESI7, with improved potency and pharmacokinetic measures. The major aim of this project will be to compare the efficacy of this compound to other tanshinone-containing herbal formulations and current Western interventions through in vitro and in vivo experiments. In vitro experiments will be conducted to determine the comparative inhibition of collagen degradation. In vivo mice experiments will be conducted to assess for bone-preserving efficacy and potential side effects after a four months period of treatment. We hope to introduce a new therapeutic treatment option for osteoporotic patients with increased efficacy in the absence of significant adverse events.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zhou, Rujing
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~